All entries for: Agios Pharmaceuticals, Inc.

February 19, 2026

Agios Pharmaceuticals, Inc.

Orphan Drug Designation

Cambridge
501-1,000 employees

treatment of sickle cell disease

Disease Area: Rare Disease
February 12, 2026

Agios Pharmaceuticals, Inc.

Neutral Outlook

Cambridge
501-1,000 employees

in May 2025, the President issued an additional executive order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the United States. The executive order directs the Secretary of HHS to communicate most-favored-nation, or MFN, price targets to pharmaceutical manufacturers to bring prices in line with comparably developed nations. The executive order further provides that if such actions do not lower the costs of pharmaceuticals, the Secretary of HHS would pursue other actions, including proposing a rulemaking that imposes MFN pricing in the United States.

Scroll to Top